Thus, the identification of Nr4a1/Ear2‐dependent anti‐inflammatory macrophage population was highly significant both scientifically and clinically since it may imply that the induction of this anti‐inflammatory macrophage population via the Nr4a1/Ear2‐dependent mechanism may represent as a novel immunotherapy for anti‐GBM cGN. The gene discussed is NR2F6; the disease is glioblastoma.